Biomea Fusion, Inc. (NASDAQ: BMEA) began Phase II testing of its lead beta‑cell restoration drug icovamenib in two distinct type 2 diabetes populations, marking the first patient dose in the newly launched COVALENT‑211 and COVALENT‑212 studies.
COVALENT‑211 targets insulin‑deficient type 2 diabetes, while COVALENT‑212 enrolls patients who remain uncontrolled on GLP‑1 receptor agonists. Each study will enroll roughly 60 participants and use a 2:1 randomization of icovamenib to placebo. The 12‑week treatment period is followed by a 40‑week off‑treatment follow‑up designed to assess durable glycemic control and beta‑cell preservation.
The dosing milestone builds on encouraging results from the Phase II COVALENT‑111 study, which showed durable HbA1c reductions that persisted for up to nine months after a 12‑week course. Topline data from COVALENT‑211 and COVALENT‑212 are expected in the fourth quarter of 2026, providing the first clinical readout of icovamenib’s efficacy in these high‑need patient groups.
Biomea Fusion’s financial position remains solid, with $56.2 million in cash and cash equivalents as of December 31 2025 and a projected runway into the first quarter of 2027. The company reported a net loss of $61.8 million for 2025, a significant improvement from $138.4 million in 2024, reflecting reduced R&D spending and disciplined capital allocation.
Interim CEO Mick Hitchcock emphasized the strategic importance of the new trials: "These studies represent an important step forward as we advance icovamenib into later‑stage Phase II development in the two clearly defined patient populations in which we had observed sustained glycemic improvements in our prior study. We are planning to enroll these two studies within the second quarter to achieve an initial readout before year‑end."
In addition to icovamenib, Biomea Fusion is developing BMF‑650, an oral GLP‑1 receptor agonist for obesity. Initial 28‑day weight‑loss data from its Phase I trial are expected in the second quarter of 2026, adding further depth to the company’s pipeline.
The first‑patient dose signals a critical progression point for Biomea Fusion, positioning the company to potentially address unmet needs in type 2 diabetes and obesity while maintaining a strong cash position and a clear path toward future clinical milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.